Literature DB >> 16689756

Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.

D Imberti1, W Ageno, F Dentali, M Giorgi Pierfranceschi, E Croci, D Garcia.   

Abstract

BACKGROUND: Out of hospital management of patients with suspected deep vein thrombosis (DVT) can be problematic. The accuracy of clinical prediction rules in the primary care setting may be inadequate, D-dimer testing may not be available, and the cost-effectiveness of urgent ultrasonographic evaluation is uncertain.
OBJECTIVE: The purpose of this study was to determine the efficacy and safety of an empiric single therapeutic dose of low-molecular weight heparin (LMWH) in the time interval preceding ultrasound investigation in patients presenting to primary care physicians (PCPs) for suspicion of DVT.
METHODS: Consecutive patients with suspected DVT who presented to the office of a PCP outside regular thrombosis center working hours were enrolled. All eligible patients received a single therapeutic dose of LMWH (100 anti-Xa IU kg(-1) weight) and were scheduled to undergo clinical and instrumental evaluation at the thrombosis center the morning after. Clinical events were documented after a 3-month follow-up.
RESULTS: A total of 534 consecutive patients with suspected DVT were included in this study; of these 102 patients had subsequent diagnosis of DVT. We detected no episodes of pulmonary embolism, major bleeding, or death during the 18-h window between the administration of LMWH and objective evaluation. Of the 432 patients in whom diagnosis of DVT was subsequently excluded, only three (0.7%; CI: 0.2-2.0%) developed venous thromboembolic events during the 3-month follow-up period.
CONCLUSIONS: Empiric treatment with a single therapeutic dose of LMWH is effective and safe for outpatients with suspected DVT initially managed in a primary care setting. This strategy has the potential to reduce the need for urgent diagnostic imaging.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16689756     DOI: 10.1111/j.1538-7836.2006.01940.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  4 in total

1.  When pre-test probability can be deceptive.

Authors:  Micaela La Regina; Maria Cristina Pierantoni; Massimo Ratti; Francesco Orlandini
Journal:  Intern Emerg Med       Date:  2010-02       Impact factor: 3.397

2.  Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis.

Authors:  Synne G Fronas; Anders E A Dahm; Hilde S Wik; Camilla T Jørgensen; Jostein Gleditsch; Nezar Raouf; René Holst; Frederikus A Klok; Waleed Ghanima
Journal:  Blood Adv       Date:  2020-06-09

3.  Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism.

Authors:  Maddie S Stephen; Lana Castellucci; Marc Carrier; Lisa Duffett; Gregoire Le Gal; Marc Rodger; Philip S Wells; Aurélien Delluc
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

4.  [Cost-effectiveness of the deep vein thrombosis diagnosis process in primary care].

Authors:  Eva Fuentes Camps; José Luis del Val García; Sergi Bellmunt Montoya; Sara Hmimina Hmimina; Efren Gómez Jabalera; Miguel Ángel Muñoz Pérez
Journal:  Aten Primaria       Date:  2015-08-19       Impact factor: 1.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.